GlassScriptPhysician profile
Sandra Maritza Jara
NPI 1003905605
$9,142.15
in general payments reported to CMS, 2019-2025
29 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $487 · 2021: $1,191 · 2022: $1,962 · 2023: $1,547 · 2024: $1,453 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,937 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,937.09 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,739.33 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,087.26 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,065.70 | 2019-2025 | Tremfya, Simponi, Stelara |
| Celgene Corporation | $485.07 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $414.57 | 2019-2025 | Entyvio, Eohilia, Takhzyro |
| Gilead Sciences, INC. | $332.42 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $303.29 | 2019-2025 | Ocaliva |
| Pfizer INC. | $234.72 | 2021-2025 | |
| Braintree Laboratories, INC. | $224.60 | 2021-2025 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $187.46 | 2023-2025 | Voquezna |
| Boston Scientific Corporation | $158.38 | 2023-2025 | Axonics, Resolution 360 Clip, Resolution 360 Ultra Clip |
| Merck Sharp & Dohme LLC | $133.22 | 2019-2024 | Dificid, Zinplava |
| Madrigal Pharmaceuticals | $122.56 | 2024-2025 | Resmetirom, Rezdiffra |
| Redhill Biopharma INC. | $107.85 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Fujifilm Healthcare Americas Corporation | $75.28 | 2023 | Fujifilm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $72.24 | 2023-2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $67.79 | 2019-2021 | |
| Vivus LLC | $55.59 | 2021-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $46.53 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $43.89 | 2024 | Iqirvo |
| Janssen Scientific Affairs, LLC | $43.71 | 2023 | Tremfya, Stelara |
| Biocon Biologics INC | $25.36 | 2025 | Yesintek |
| Exact Sciences Corporation | $24.86 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Shire North American Group INC | $16.13 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.24 | 2024 | Rebyota |
| Alfasigma USA, INC. | $15.12 | 2020 | |
| Shionogi INC | $14.37 | 2019 | |
| Ardelyx, INC. | $13.31 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Jara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.